Cooper University HealthCare | MD Anderson Cancer Center at Cooper

Research site

Site insights

Top conditions

Top treatments


Parent organization

This site is a part of Cooper University HealthCare

Data sourced from

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 28 total trials

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with di...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Breast Cancer
Drug: Trastuzumab Emtansine
Drug: Placebo

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination wit...

Relapsed or Refractory Follicular Lymphoma
Drug: Lenalidomide
Drug: Rituximab

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting
Newly Diagnosed
Drug: Placebo Oral Tablet
Drug: Rucaparib

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Drug: 5-Fluorouracil
Drug: Tislelizumab

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of...

Multiple Myeloma
Drug: Selinexor
Drug: Elotuzumab

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase...

Solid Tumor
Drug: Farletuzumab ecteribulin
Drug: Prednisolone

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetax...

Prostate Cancer
Drug: Radium-223
Drug: Docetaxel 60 mg/m2

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continua...

Active, not recruiting
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patient...

Active, not recruiting
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Other: Best Standard of Care
Device: NovoTTF-200M device

This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placeb...

Active, not recruiting
Cervical Cancer
Drug: AGEN2034
Drug: AGEN1884

The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenanc...

Active, not recruiting
Peritoneal Neoplasms
Fallopian Tube Cancer
Drug: Docetaxel
Drug: Placebo for olaparib

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combinatio...

Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum r...

Active, not recruiting
Platinum-resistant Ovarian Cancer
Drug: Afuresertib
Drug: Paclitaxel

Trial sponsors

Cooper University Health Care logo
Roche logo
Abramson Cancer Center at Penn Medicine logo
Agenus logo
BeiGene logo
Daiichi Sankyo logo
Eisai logo
Genmab logo
ImmunoGen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems